Communiqués Natera, Inc.

Actions

NTRA

US6323071042

Installations et services en soins de santé

Marché Fermé - Nasdaq 22:00:00 02/10/2026			Varia. 5j.	Varia. 1 janv.
410,35 ^USD	+0,46%		-0,54%	+79,12%

25/09	Le Signatera Genome de Natera pourrait devenir l’offre clinique dominante d’ici quelques années, selon RBC	MT
25/09	Natera, Inc. : RBC Capital Markets optimiste sur le dossier	ZM

Communiqués

23/09	Natera, Inc. - Signatera Receives Regulatory Approval in Japan as a Companion Diagnostic in Muscle-Invasive Bladder Cancer	AQ
22/09	Signatera™ Receives Regulatory Approval in Japan as a Companion Diagnostic in Muscle-Invasive Bladder Cancer	BU
18/09	Largest MRD Study in Lung Cancer Highlights Strong Prognostic Value for SignateraTM	BU
01/09	New Publication Establishes Strong Clinical Validation of Signatera™ for MRD Assessment in Lymphoma	BU
31/08	Natera and Susan G. Komen Announce National Partnership to Accelerate Progress against Breast Cancer	AQ
28/08	Natera and Susan G. Komen® Announce National Partnership to Accelerate Progress Against Breast Cancer	BU
27/08	Natera and Angiex Partner to Assess Response to Investigational Nuclear-Delivered Antibody-Drug Conjugate™ Using Signatera™	BU
13/08	Natera to Support New Clinical Trial Assessing ctDNA Dynamics with Latitude in Advanced Skin Cancers	AQ
12/08	Natera to Support New Clinical Trial Assessing ctDNA Dynamics with Latitude™ in Advanced Skin Cancers	BU
07/08	Natera : Q2 2026 Earnings Presentation	PU
06/08	Natera: Q2 Earnings Snapshot	AQ
06/08	Natera Reports Second Quarter 2026 Financial Results	BU
05/08	Natera Submits Signatera™ to Japan’s PMDA for Approval as a Companion Diagnostic in Muscle-Invasive Bladder Cancer	BU
30/07	Natera to Report its Second Quarter Results on August 6, 2026	BU
22/07	Signatera™ MRD Outperformed AMERK Testing in Predicting Merkel Cell Carcinoma Recurrence in JAMA Dermatology Study	BU
17/07	Finalized MolDx LCD Includes Expanded Coverage for Natera’s Prospera™ Portfolio	BU
09/07	Natera Announces IVDR Certification for Signatera™ Across Multiple Cancers	BU
06/07	Signatera™ MRD Test Predicted Overall Survival Benefit from Chemotherapy in Resected Metastatic Colorectal Cancer	BU
29/06	Natera and Aveta Biomics Announce Strategic Partnership Supporting Global Phase 3 Registrational Trial of APG-157 in Head and Neck Cancer	BU
25/06	Natera, Inc. - Signatera Receives Regulatory Approval in Japan for Colorectal Cancer	AQ
25/06	Natera and Eledon Announce Strategic Partnership for Prospera™ Monitoring in Planned Phase 3 Kidney Transplant Trial	BU
24/06	Signatera™ Receives Regulatory Approval in Japan for Colorectal Cancer	BU
24/06	Signatera™ Receives Regulatory Approval in Japan for Colorectal Cancer	BU
23/06	NCCN Recommends ctDNA-MRD Testing Using Signatera™ Technology in Landmark Bladder Cancer Guideline Update	BU
22/06	Pirche Announces Partnership to Advance Transplant Medicine by Combining Pre-Transplant Risk Stratification and Post-Transplant dd-cfDNA Monitoring	AQ